Company to host conference call at 4:30 PM EDT today, August 11, 2022 SEATTLE, Wash and VANCOUVER, British Columbia, August 11, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2022 financial…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, July 28, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, July 1, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued inducement grants of stock options to two new employees. Achieve’s Board of Directors…
/Read More
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial. ORCA-V1 will evaluate the…
/Read More
SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the H.C. Wainwright 1st Annual Mental Health Conference. The Conference is…
/Read More